Fibrates protect against vascular endothelial dysfunction induced by paclitaxel and carboplatin chemotherapy for cancer patients: a pilot study

Background Although we previously demonstrated that paclitaxel and carboplatin chemotherapy (TCchem) is associated with vascular toxicities, the underlying mechanisms remain unclear. Cisplatin is known to inhibit PPARα following microvascular damage to the kidneys. The primary aim of this study was...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical oncology 2015-08, Vol.20 (4), p.829-838
Hauptverfasser:	Watanabe, Ayako, Tanabe, Akiko, Maruoka, Risa, Nakamura, Kiyoko, Hatta, Koji, Ono, Yoshihiro J., Terai, Yoshito, Ohmichi, Masahide
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Bezafibrate - pharmacology Bezafibrate - therapeutic use Cancer Cancer Research Carboplatin - adverse effects Carboplatin - pharmacology Carboplatin - therapeutic use Chemotherapy Endothelium, Vascular - drug effects Female Genital Neoplasms, Female - drug therapy Gynecology Humans Medicine Medicine & Public Health Middle Aged Nitric Oxide - biosynthesis Oncology Original Article Paclitaxel - adverse effects Paclitaxel - pharmacology Paclitaxel - therapeutic use Pilot Projects PPAR alpha - antagonists & inhibitors PPAR alpha - metabolism Preventive medicine Surgical Oncology Toxicity Triglycerides Triglycerides - blood Umbilical Veins - drug effects Vascular Diseases - chemically induced Vascular Diseases - prevention & control Vasodilator Agents - pharmacology Vasodilator Agents - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!